VacZine Analytics  
MarketVIEW: Acinetobacter baumannii vaccines

Updating: May 2019

Acinetobacter baumannii (AB) of the Acinetobacter spp is a ubiquitous aerobic Gram-negative bacillus which preferentially colonises aquatic environments. Because of its high propensity for antimicrobial resistance, the bacterium has become a WHO “Priority No 1” pathogen and poses a critical threat to global human health. AB is associated with around ~1-2% of hospital-acquired infections (HAIs) where colonization is associated with an increased risk of hospital death. Patients usually affected are the critically ill and/or immune-compromised, having been admitted to the intensive care unit (ICU) and often receiving mechanical ventilation. In these instances, AB pneumonia can have high mortality rates (>50%) and importantly, infections can be challenging to treat with current antibiotics especially multidrug-resistant forms MDR, XDR and PDR. AB resistant infections dramatically increase hospital length of stay (LOS) and economic cost.

There are many drivers to justify the search for new management techniques to A.baumannii infections especially immunologic approaches such as prophylatic vaccines and monoclonal antibodies. Several companies have an ongoing preclinical interest such as ALOPEXX, Vaxdyn and Aridis Pharmaceuticals and larger manufacturers would be well advised to be involved. Acinetobacter baumannii is a unique concern, and it is not prudent to evaluate AB alongside high volume comparators that also have an antimicrobial resistance threat.

This MarketVIEW product is composed of a comprehensive Executive summary presentation (~100 slides, .pdf) + MS Excel-based model which forecasts the potential commercial value of a putative Acinetobacter baumannii vaccine across major Western markets to 2030. Three deployment scenarios (LO, BASE and HI) are included based upon successive targeting of patient groups (and specific subsets) who would benefit from vaccination. A detailed review of disease background and epidemiology is included along with current treatment, unmet needs and rationale for vaccine approach. An ideal Target Product Profile (TPP) is defined along with commercial model assumptions with economic pricing justification. This analysis is ideally suited to any organisation wishing to understand and justify investment into this highly important opportunity.


THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf, 100 slides) + 1 MODEL (.xls, 55 worksheets)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV070 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2017 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains